TherOZap™

Next Generation Thermal Therapy Insect Device

Mosquitos, bees, spiders, mites, and jellyfish love to bite or sting! Unfortunately, attacks from these, and other pests, may leave us with painful, itchy and inflamed skin- or worse yet a nasty virus!

The Jenex Corporation, the former company name before the name change to Therma Bright Inc., received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). The Jenex Corporation received approval for the above claims from FDA (United States) in 1997. The 510K in the name of The Jenex Corporation is currently not licensed in the US under Therma Bright Inc.  The Company expects to transfer the 510K from The Jenex Corporation to Therma Bright Inc. as it completes R&D and readies its product for commercialization.

Introducing TherOZap™ – the next generation thermal therapy insect device. The TherOZap™ thermal therapy will aim to reduce the inflammatory response, relieving the symptoms of pain, itch and inflammation associated with insect bites and stings.

Currently, Therma Bright has been working with engineers and designers to complete a prototype that will be tested for effectiveness against the Zika virus and other mosquito borne diseases.  Once testing is complete Therma Bright will seek any regulatory approvals and outsource manufacturing and distribute TherOZap™ through distribution partners and online through social media channels.